Dr Karan Rajan, an NHS surgeon and University of Sunderland lecturer, has shared his thoughts on 'menstrual blood-derived ...

Frankl believed that life can be made meaningful in a three-fold way: through what we give (in terms of creative work), from ...

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

Ta-1505 is under clinical development by Merck and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate ...

新型生物标志物的发现和新型治疗药物的问世， 标志着阿尔茨海默病在诊断与治疗方面有了突破性的进展 ，相信在未来的临床研究中可能会发现准确性更高的生物标志物和疗效更确切、不良反应更少、更加便捷的药物，从而 延缓阿尔茨海默病的病情进展及改善患者的生活质量 ...

NA-831 is under clinical development by Biomed Industries and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 12% phase ...

Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.

TAMPA, Fla. - Every year, about 500,000 people are diagnosed with Alzheimer's disease. For many, the holidays are a key time ...

Nearly 80% of caregiving for people with Alzheimer’s disease or dementia occurs in the home but most caregivers don’t realize ...

Researchers at the University of Illinois have found that a gene editing tool allows them to “skip” genes that lead to ...

Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...